Clinical Trials Browser

Active not recruiting × Urologic Neoplasms × 30 days × Clear all

Breast Neoplasms, Urologic Neoplasms

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3 Active not recruiting

60 enrolled 15 charts

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT06238479 2026-04-13

EXCEED

Phase 1 Active not recruiting

490 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Savolitinib vs. Sunitinib in MET-driven PRCC.

EXCEED